Ekso Bionics Announces Partnership with U.S. Physiatry to Support Physician Education of EksoNR
March 09 2021 - 8:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced a partnership with U.S. Physiatry
(USP) to educate physicians on the clinical benefits of an EksoNR
exoskeleton. USP is the largest inpatient physician practice in the
U.S. focused exclusively on physical medicine and rehabilitation.
The partnership will help expand awareness of Ekso Bionics’
technology among physicians and other rehabilitation clinicians as
well as educate on how to successfully implement robotics into a
rehabilitation program.
“The EksoNR exoskeleton is a powerful
robotic-assisted rehabilitation tool that will allow our expert
physiatrists to enhance the lives of thousands of individuals by
improving their rehabilitation and recovery,” said Craig DiTommaso,
M.D., Director of Early Career Physician Development at U.S.
Physiatry.
USP is a physician-led group of physiatrists who
are currently practicing rehabilitation medicine. Their goals are
to ensure the success of the physiatrist by providing the resources
of a national company. As part of the partnership, USP’s
physiatrist team of experts will lead a four-part lecture series
that will be open to other physicians, clinicians, and other
healthcare leaders across the U.S. Topics will include EksoNR
education, research and development, best practices on Ekso program
implementation, and general marketing of an EksoNR.
“We are excited to partner with USP and their
commitment to patient care in demonstrating the value of our
cutting-edge exoskeleton device,” said Rachael Adams, Global
Director of Marketing and Strategic Growth of Ekso Bionics. “EksoNR
is the most studied exoskeleton on the market today that has been
proven to enhance patient outcomes, making it a strategic
differentiator for stroke centers.1 Effectively educating
clinicians and physicians on the clinical and economic value of
starting an EksoNR program has always been a priority for our team.
By partnering with USP’s deep network of physiatrists, we believe
our shared patient-focus strategies will help build awareness for
our platform of technologies across the post-acute care
market.”
The first webinar of the series is scheduled for
Thursday, April 8th at 12:00pm CT, with future dates to soon be
announced for the remaining lectures, and will be available on
www.eksobionics.com.
About Ekso
Bionics®Ekso Bionics® is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance, and mobility across
medical and industrial applications. Founded in 2005, Ekso Bionics
continues to build upon its industry-leading expertise to design
some of the most cutting-edge, innovative wearable robots available
on the market. Ekso Bionics is the only exoskeleton company to
offer technologies that range from helping those with paralysis to
stand up and walk, to enhancing human capabilities on job sites
across the globe. Ekso Bionics is headquartered in the San
Francisco Bay Area and is listed on the Nasdaq Capital Market under
the symbol “EKSO.” For more information, visit: www.eksobionics.com
or follow @EksoBionics on Twitter.
About U.S. PhysiatryUS
Physiatry (USP) was founded in 2011 as it became evident that
another round of Healthcare reform was imminent. Founded by
rehabilitation leaders from all aspects of the rehab continuum, USP
decided to focus on rehabilitation in all of the current settings
so that both the rehab patient and the physiatrist will be well
represented when changes are implemented. USP’s goals are to ensure
the success of the physiatrist by providing the resources of a
national company to help negotiate managed care contracts, ACO
affiliations, implement an IT strategy that will allow us to focus
on quality outcomes, and ensure that the revenue cycle is the best
possible for a physiatrist. USP believes that empowering the rehab
physician to follow a patient throughout the rehab continuum will
allow for the best possible outcomes for patients and is also the
best way for our physician partners to maximize their income
opportunities.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding the potential benefits, performance and
effectiveness of the Company’s products and systems, including
EksoNR, market awareness and acceptance of the Company’s products
and technology, and the assumptions underlying such statements.
Such forward-looking statements are not meant to predict or
guarantee actual results, performance, events or circumstances and
may not be realized because they are based upon the Company’s
current projections, plans, objectives, beliefs, expectations,
estimates and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the ongoing COVID-19 pandemic and its
impact on the Company’s financial condition and business, the
highly competitive markets in which the Company’s products are
sold, the Company's significant losses to date and anticipated
future losses, the new and unproven nature of the market for the
Company’s products, the long and variable sales cycles for the
Company’s products, the factors outside the Company’s control that
affect the international sales of its products, the costs related
to and impacts of potential failure of the Company to obtain or
maintain protection for the Company's intellectual property rights,
the failure of the Company to obtain or maintain regulatory
approval to market the Company's medical devices, and risks related
to product liability, recall and warranty claims. These and other
factors are identified and described in more detail in the
Company’s filings with the U.S. Securities and Exchange Commission.
To learn more about Ekso Bionics please visit the Company’s website
at www.eksobionics.com or follow @EksoBionics on Twitter. The
Company does not undertake to update these forward-looking
statements.
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
1
https://eksobionics.com/wp-content/uploads/2020/08/Clinical_Summary_JUNE-2020.pdf
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024